If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
An Italian SME, spin-off from academy, has patented a "nanostructured microsponges" solution made of hyaluronic acid (NPHA) for applications in a drug-delivery, injectable medical devices or fillers in cosmetics. Proven to be safe/lasting for more than 8 weeks after injection, the product can compete amongst best in class technologies. It is applicable for the treatment of osteoarthritis or rheumatoid arthritis.
Licence, financial and joint venture agreements are sought.
The treatment of osteoarthritis by intra-articular injection of hyaluronic acid (HA) is a major medical applications in our aging society - and a "big" business in medical industry. To reduce the financial burden and improve on quality of life of patients, a better HA is needed. The first problem faced and solved has been the limited residency of HA after injection. Current (best) products certified as medical devices for this usage have a declared release time-span limited to up a few weeks. On the contrary, the innovative cross-linked hyaluronic acid nanoporous particles (NPHA) can last for a few months, bringing up a glaring business and a clinical opportunity for a step-change. Having gathered scientific evidence of NPHA effectivity and safety, and having successfully engaged with an IP management process, the Italian SME is at a point where the technology could be licensed to a global company of Pharmaceutical and Medical Device Sectors.
In addition, the pharmaceutical industry is facing challenges related to dosage optimization of drugs. In this respect, the NPHA has the unique opportunity to function as long-lasting excipient or carrier for drug delivery at the end of pharmaceutical approval (recall most competing branded products are approved as medical device only in EU). The uptaking and disscharge of molecule (regardless of the electrical sign) has been fully proven at lab scale, with a characteristic release profile.
In summary, this promising technology has manyfold applications, as it could be licensed for exploitation in the medical device and pharmacological markets, making NPHA possibly the slowest release product available today, as well as a unique option for drug delivery and dosage optimization. Cosmetics (fillers) is a rich market where the NPHA can be deployed succesfully too.
Licence, financial and join venture Agreement are sought
The company is looking for the following cooperation types:
• license agreement: licensing for the use of the developed tecnology in order the partner can use them to develop its own application;
• financial Agreement: to create industrial initiative to promote the company production in the market.
• joint venture agreement: the company can transfer to the NewCo th eproduction and tecnology in order to provide customised solution for specific needs.
With respect to injectable product, NPHA is not necessarily cheap or cheaper than competing products (at same dosage), but it is new, unique and last longer. WIth a cost of 200-350€ for the premium one-shot products, NPHA could outperform the competition even at lower price point and result in overall savings for patients and national health systems.
The NPHA has the potential both to be "a best in class" product in the market of injectable HA and an entirely unique product for drug delivery, providing a safe and innovative point-of-care delivery. As such, there are no really current product from the competition.
Furthermore, the NPHA is manufactured by a near one-pot synthesis process that can be easily scaled up in an industrial setup, which is appealing .
The development at pre-clinical level is at an advanced stage and the production has been scaled up in the laboratory. NPHA are already sold in small quantity for selected research applications. For human application it could be brought with minimum effort first into the cosmetics market, provided the completion of a pre-clinical trial and the setting up a "Good Manufacturing Practices" (GMP) production. Following more involved tests and clinical trials, NPHA could enter the injectable device market and later the pharmaceutical market.
Technology patented in EU and Japan
Licensees by region and by market sector, mainly from Countries where NPHA is patented (e.g. Japan)
FInancial investors of joint-venture (with part of financial investment) able to support at least the IP strategy for 3 years and the completion of market lauch in cosmetics, to ignite and self-sustain the global exploitation of the technology.